EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

A Double‐Blind Randomised Clinical Trial of Terbinafine‐Nanostructured Lipid Carriers: Should We Anticipate This Strategy for Effective Topical Treatment of Onychomycosis?

Shima Parsay, Majid Saeedi, Mahdi Abastabar, Mohammad Taghi Hedayati iD, Seyyed Mobin Rahimnia, Nasim Gholizadeh, Armaghan Kazeminejad, Katayoun Morteza-Semnani, Roozbeh Zare Gashti, Kofi Asare-Addo, Maryam Moazeni, Ali Nokhodchi iD

Mycoses · 2025

DOI: 10.1111/myc.70076 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Mycoses, 2025. Verfasst von Shima Parsay und 11 weiteren Autor:innen. Beteiligte Einrichtung: Student Research Committee, Mazandaran University of Medical Sciences, Sari, Iran. Hauptthemen laut MEDLINE: Terbinafine, Onychomycosis, Antifungal Agents, Drug Carriers. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Medical Research Development, Mazandaran University of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Oral terbinafine (TBF) is the drug of choice for onychomycosis management. To treat and heal the rough and thick nail tissue affected by fungal agents, a high dose and plasma concentration of this drug is necessary. This, however, poses a life‐threatening risk due to the cytotoxic side effects, drug–drug interactions, and adverse physical and chemical properties associated with oral medications.

Objectives

This study aimed to employ nanostructured lipid carriers (NLCs) in a gel formulation to avoid side effects and to increase the absorption of topical TBF.

Methods

Terbinafine‐loaded nanostructured lipid carriers (TBF‐NLCs) were developed and optimised using an ultrasonic probe technique, resulting in the formulation of TBF‐NLCs as a 1% w/w carbopol gel after verifying the characteristics associated with NLCs. In vitro antifungal susceptibility test (AFST) was conducted on 85 prevalent fungal species associated with onychomycosis, as well as on strains isolated from trial participants, following the CLSI M38‐A2 and M27‐A3 guidelines. A total of 60 volunteers were enrolled in this clinical randomised, double‐blind, placebo‐controlled study, divided equally into three groups prescribed with TBF cream 1%, TBF‐NLCs gel 1%, and a placebo.

Results

A monodisperse suspension of spherical nanoparticles was successfully produced, exhibiting a zeta potential of 18.4 ± 1.02 mV, a Z‐average of 131.7 ± 5.32 nm, a PDI index of 0.280 ± 0.017, and an EE percentage of 83.51 ± 3.52, all without any cytotoxic effects. The severity index showed a reduction from 65% and 55% to 35% and 10% in the TBF cream 1% and TBF‐NLCs groups, respectively. From a mycological perspective, no significant negative results were noted during the 6th and 8th weeks of TBF‐NLC 1% gel application.

Conclusion

The application of TBF‐NLCs gel 1% demonstrated a quicker clinical recovery without adverse side effects compared to TBF cream, thus highlighting the effective nature of NLCs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TerbinafineOnychomycosisAntifungal AgentsDrug CarriersLipidsNanostructuresHumansDouble-Blind MethodMaleFemaleAdultMiddle AgedAdministration, TopicalMicrobial Sensitivity TestsYoung AdultTreatment OutcomeAgedFungi

Stichwörter der Autor:innen

NLCsTBF‐NLC 1% gelantifungal susceptibility testclinical trialmycological perspectiveonychomycosisseverity indexterbinafine

Substanzen

TerbinafineAntifungal AgentsDrug CarriersLipids

Autor:innen und Institutionen

  • Student Research Committee, Mazandaran University of Medical Sciences, Sari, Iran.
  • Department of Pharmaceutics, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.
  • Pharmaceutical Sciences Research Centre, Haemoglobinopathy Institute, Mazandaran University of Medical Sciences, Sari, Iran.
  • Department of Medical Mycology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
  • Invasive Fungi Research Center, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran.
  • Department of Dermatology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.

ORCID-Profile: Mohammad Taghi Hedayati, Ali Nokhodchi

Förderung

  • National Institute for Medical Research Development
  • Mazandaran University of Medical Sciences

Zitieren

APA

Parsay, S., Saeedi, M., Abastabar, M., Hedayati, M. T., Rahimnia, S. M., Gholizadeh, N., Kazeminejad, A., Morteza-Semnani, K., Gashti, R. Z., Asare-Addo, K., Moazeni, M., & Nokhodchi, A. (2025). A Double‐Blind Randomised Clinical Trial of Terbinafine‐Nanostructured Lipid Carriers: Should We Anticipate This Strategy for Effective Topical Treatment of Onychomycosis?. Mycoses. https://doi.org/10.1111/myc.70076

Vancouver

Parsay S, Saeedi M, Abastabar M, Hedayati MT, Rahimnia SM, Gholizadeh N, et al. A Double‐Blind Randomised Clinical Trial of Terbinafine‐Nanostructured Lipid Carriers: Should We Anticipate This Strategy for Effective Topical Treatment of Onychomycosis?. Mycoses. 2025. doi:10.1111/myc.70076

BibTeX
@article{Parsay2025,
  author = {Parsay, Shima and Saeedi, Majid and Abastabar, Mahdi and Hedayati, Mohammad Taghi and Rahimnia, Seyyed Mobin and Gholizadeh, Nasim and Kazeminejad, Armaghan and Morteza-Semnani, Katayoun and Gashti, Roozbeh Zare and Asare-Addo, Kofi and Moazeni, Maryam and Nokhodchi, Ali},
  title = {A Double‐Blind Randomised Clinical Trial of Terbinafine‐Nanostructured Lipid Carriers: Should We Anticipate This Strategy for Effective Topical Treatment of Onychomycosis?},
  journal = {Mycoses},
  year = {2025},
  doi = {10.1111/myc.70076}
}
Kostenlos starten →